20 years of cardiovascular care advancements save more lives

Big leaps take heart and vascular care from science fiction to standard procedure at the Ohio State Richard M. Ross Heart Hospital.

Author: Wendy MargolinBryan Whitson in research lab

When Ernest Mazzaferri Jr., MD, reflects on how heart and vascular care has changed in the past 20 years at The Ohio State University Wexner Medical Center Richard M. Ross Heart Hospital, he can’t help but evoke the memory of his father. “My dad was a physician and used to say he would give anything to see where medicine will be in 100 years,” says Dr. Mazzaferri.Heart and vascular care is changing so rapidly now that it’s hard to imagine patient care in the next five years, let alone 100.What seems like decades of advancement occurs every few years, making cardiovascular care feel more like science fiction than reality. “You can’t practice cardiology like you did even three years ago, or you’re out of date,” Dr. Mazzaferri says.

Five major advancements in cardiovascular care

Thanks to less invasive treatments, preventive medicine and better screening and treatment technology, more patients than ever are living longer, healthier lives.Five major advancements in cardiovascular care illustrate how patient outcomes have improved in the two decades since the Ohio State Richard M. Ross Heart Hospital opened its doors in 2004.

Read the full story on the Health and Discovery Website.

Featured Publications

Townsend_Kristy_720x720

Gene therapy approaches for obesity-induced adipose neuropathy: Device-targeted AAV-mediated neurotrophic factor delivery to adipocytes in subcutaneous adipose

Kristy Townsend, PhD

"Maintaining functional adipose innervation is critical for metabolic health. We found that subcutaneous white adipose tissue (scWAT) undergoes peripheral neuropathy (PN) with obesity, diabetes, and aging (reduced small-fiber innervation and nerve/synaptic/growth-cone/vesicle markers, altered nerve activity). Unlike with nerve injuries, peripheral nerves do not regenerate with PN, and therefore new therapies are needed for treatment of this condition affecting 20-30 million Americans. Here, we validated a gene therapy approach using an adipocyte-tropic adeno-associated virus (AAV; serotype Rec2) to deliver neurotrophic factors (brain-derived neurotrophic factor [BDNF] and nerve growth factor [NGF]) directly to scWAT to improve tissue-specific PN as a proof-of-concept approach."

Read on PubMed

Kyriazis_George_720x720

The TAS1R2 G-protein-coupled receptor is an ambient glucose sensor in skeletal muscle that regulates NAD homeostasis and mitochondrial capacity

George Kyriazis, PhD

"The bioavailability of nicotinamide adenine dinucleotide (NAD) is vital for skeletal muscle health, yet the mechanisms or signals regulating NAD homeostasis remain unclear. Here, we uncover a pathway connecting peripheral glucose sensing to the modulation of muscle NAD through TAS1R2, the sugar-sensing G protein-coupled receptor (GPCR) initially identified in taste perception."

Read on PubMed

Deqiang Li

Endocardial HDAC3 is required for myocardial trabeculation

Deqiang Li, PhD & Vidu Garg, MD

“Failure of proper ventricular trabeculation is often associated with congenital heart disease. Support from endocardial cells, including the secretion of extracellular matrix and growth factors is critical for trabeculation. However, it is poorly understood how the secretion of extracellular matrix and growth factors is initiated and regulated by endocardial cells… Our findings provide insights into the pathogenesis of congenital heart disease and conceptual strategies to promote myocardial regeneration.”

Read on PubMed


Radwanski_Przemyslaw_720x720

Mitigates Dravet Syndrome-Associated Sudden Death in Adults

Przemyslaw Radwanski, PhD

Radwanski, Veeraraghavan, Hund, Weinberg, & Nassal

"In this study, the authors sought to provide evidence implicating remodeling of Na+ - and Ca2+ -handling machinery, including NaV 1.6 and Na+/Ca2+exchanger (NCX) within transverse (T)-tubules in DS-associated arrhythmias."

Read on PubMed

Mallampalli_Rama_724x840

Targeted degradation of extracellular mitochondrial aspartyl-tRNA synthetase modulates immune responses

Rama Mallampalli, MD

“The severity of bacterial pneumonia can be worsened by impaired innate immunity resulting in ineffective pathogen clearance. We describe a mitochondrial protein, aspartyl-tRNA synthetase (DARS2), which is released in circulation during bacterial pneumonia in humans and displays intrinsic innate immune properties and cellular repair properties… Here, we show a unique biological role for an extracellular, mitochondrially derived enzyme and its molecular control by the ubiquitin apparatus, which may serve as a mechanistic platform to enhance protective host immunity through small molecule discovery.”

Read on PubMed

WEXMED Live

Click below to see WEXMED Live Talks by members of DHLRI.

WEXMED Live Talks

WEXMED Live Website

Past Featured Publications

Spring 2024

Past Stories